Boston Scientific taps ex-Covidien CFO Dockendorff, Hologic CEO MacMillan for board | Personnel Moves
HeartFlow
SNN invests in Michelson’s Series B | Medtech funding for the week of February 16, 2015
JenaValve taps medtech vet Keltjens for interim CEO | Personnel Moves
JenaValve tapped a medtech veteran with a string of successful exits behind him as interim chairman & CEO, replacing another medical device vet, David Drachman, after just 7 months.
FDA green lights Stimwave’s mini spinal cord stimulator | Regulatory news for the week of December 8, 2014
FDA gives the green light to Stimwave's mini spinal cord stimulator
December 3, 2014 by Mark Hollmer
HeartFlow wins FDA OK for non-invasive FFR system
By Brad Perriello and Mark Hollmer
GI Dynamics swaps CEOs | Personnel Moves
Mixed results for HeartFlow’s CT-based FFR tests for coronary artery disease
HeartFlow’s non-invasive fractional flow reserve technology failed to meet pre-determined rates of accuracy in a recent clinical trial, but researchers and clinicians remained optimistic that the new system may yet replace invasive testing for coronary artery disease.
In the DeFACTO study, which enrolled more than 250 patients, FFR based on computed tomography imaging beat invasive FFR in identifying lesions and produced higher per-patient sensitivity.
St. Jude launches Asian FFR economics study
St. Jude Medical (NYSE:STJ) is launching a study to examine the economics of coronary interventions using fractional flow reserve in Japan, China, India, Korea, and Australia.
The analysis, based on the results of the Fame trial comparing FFR-guided procedures with those guided by angiography, plus statistics from country-specific percutaneous coronary intervention registries and other studies.
Cordis CSO Rogers departs for HeartFlow | Personnel Moves
Campbell Rogers is leaving his post as chief scientific officer for Johnson & Johnson’s (NYSE:JNJ) Cordis Corp. – a role created for him in July 2006 – to take the chief medical officer job at startup HeartFlow.
Cordis CSO Rogers departs for HeartFlow
Campbell Rogers is leaving his post as chief scientific officer for Johnson & Johnson’s (NYSE:JNJ) Cordis Corp. – a role created for him in July 2006 – to take the chief medical officer job at startup HeartFlow.
